Figure 4
From: Kallistatin treatment attenuates lethality and organ injury in mouse models of established sepsis
Delayed kallistatin treatment improves survival in cecal ligation and puncture (CLP) mice and lipopolysaccharide (LPS)-induced endotoxemic mice. (A) Mice receiving human kallistatin (20 mg/kg, KS20) presented significantly reduced mortality during the observation period compared to CLP control mice (PBS group); sham-operated mice exhibited 100% survival (n = 16). (B) Mice receiving human kallistatin (20 mg/kg, KS20) exhibited significantly reduced mortality rate during the observation period compared to LPS control mice (n = 16). *P <0.05 versus CLP control group or LPS control group.